Episode 138: Life Lessons From An Entrepreneur With Tom Harari

Episode 138: Life Lessons From An Entrepreneur With Tom Harari

In another change-of-pace episode, Chadi hosts Tom Harari, MBA, serial entrepreneur and writer of personal finance, business, and self-improvement. Tom shares his personal business ventures and professional story to date, opens up about how heartbreak in his personal life was a truly life-changing moment from which to grow, and recaps his viral Twitter thread of the “38 lessons I’d tell my 18 year old self.” There are plenty of advice nuggets and thought-provoking tidbits from this honest and self-reflective dialogue about how to better your life and set yourself up for future success.

Related Resources

Read Tom’s recent writings and subscribe to his newsletter: https://soloist.beehiiv.com/

Subscribe to Healthcare Unfiltered

Other Episodes You May Enjoy...

Episode 223: From Lab to Statup: Dr. Simrit Parmar on Launching Cellenkos

Dr. Simrit Parmar, founder of Cellenkos, joins the show to discuss her journey from the lab to the biotech startup world, detailing the inspiration behind launching her company, the challenges of securing funding, and the resilience required to overcome rejections. She shares insights into Cellenkos’ lead product, its progress toward market approval, and the rigorous

Read More

Episode 222: Language Matters: A Patient Perspective

Carol Rausch—a healthcare professional, cancer researcher, and former patient with lymphoma—shares how her journey from researcher to patient transformed her understanding of medical language. She discusses the impact of word choice on patients, why certain battle and war metaphors can be harmful, and how language used in clinical settings differs from what resonates with those

Read More

Episode 221: Major Progress in Adjuvant Renal Cell Carcinoma

Drs. David Braun and Toni Choueiri join to discuss a groundbreaking Nature study on a personalized neoantigen vaccine for adjuvant renal cell carcinoma. They explore the inspiration behind the trial, how the vaccine was developed and administered, and its safety profile. The conversation also covers patient outcomes after 3-4 years, including immune responses and disease

Read More